Business & regional news

Month Year

Email alerts

May 4, 2024

SCAI 2024: Medtronic transcatheter therapies show excellent outcomes in the treatment of congenital heart disease and severe aortic stenosis

Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...
- Structural Heart and Aortic
Mar 11, 2024

New late-breaking data from Medtronic Evolut™ Low Risk Trial demonstrate strong clinical and cost-effectiveness benefits of TAVR platform

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years
- Structural Heart and Aortic
Oct 12, 2023

Medtronic receives CE Mark for Evolut™ FX TAVI System for treatment of severe aortic stenosis

Next-Gen Evolut FX TAVI system enhances procedure ease-of-use, visualization, and predictability
- Structural Heart and Aortic
Aug 23, 2023

Medtronic announces first patient treated in global collaboration with Cydar Medical

40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency
- Structural Heart and Aortic
May 20, 2023

Medtronic Harmony™ Transcatheter Pulmonary Valve Only System of its Kind to Present Successful Outcomes for Congenital Heart Disease Patients at Two Years

SCAI 2023 Scientific Sessions: Harmony™ Transcatheter Pulmonary Valve System Demonstrates Strong Clinical and Hemodynamic Outcomes at Two Years
- Structural Heart and Aortic
- Photos 1

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa